Prognostic and Predictive Value of Centrally Reviewed Ki-67 Labeling Index in Postmenopausal Women With Endocrine-Responsive Breast Cancer: Results From Breast International Group Trial 1-98 Comparing Adjuvant Tamoxifen With Letrozole
Tarih
2008Yazar
Coates, Alan S.
Mastropasqua, Mauro G.
Neven, Patrick
Orosz, Zsolt
Olszewski, Wojciech P.
Knox, Fiona
Thuerlimann, Beat
Price, Karen N.
Castiglione-Gertsch, Monica
Gelber, Richard D.
Gusterson, Barry A.
Goldhirsch, Aron
Viale, Giuseppe
Giobbie-Hurder, Anita
Regan, Meredith M.
Dell'Orto, Patrizia
Maiorano, Eugenio
MacGrogan, Gaetan
Braye, Stephen G.
Oehlschlegel, Christian
Üst veri
Tüm öğe kaydını gösterÖzet
Purpose To evaluate the prognostic and predictive value of Ki-67 labeling index (LI) in a trial comparing letrozole (Let) with tamoxifen (Tam) as adjuvant therapy in postmenopausal women with early breast cancer.
Koleksiyonlar
- Makale [92796]